An Early Phase 1 interventional study of Ringer and Voluven in Hypotension Drug-Induced, sponsored by Assiut University. Status unknown. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-15.
Sponsored by Assiut University · Early Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hypotension by Assiut University — 6 open to participants now, 6 under way, 1 of them phase 3. Hypotension · Assiut University.
Among the 16 studies in Hypotension by Assiut University, this one is the 11th largest by planned enrollment, is one of 3 that started in 2018, is one of 3 in phase 1, and was the 5th registered.
893 studies on the registry are indexed under Hypotension; 197 are open to participants now.
Browse Hypotension studies →6 of the 16 studies in Hypotension by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University · Sites in Egypt
Ages 18–70
Assiut University · Sites in Egypt
Ages 19–40 · Women only
Assiut University · Sites in Egypt
Ages 65+
Assiut University
Ages 18–65
Assiut University
Ages 18–70
By country, each count listing its studies:
Of the 112 Hypotension studies recruiting now, 51 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 2 · Phase 4 2
First in 2016; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 86 across 592 interventional studies indexed under Hypotension.
Median enrollment 95 across the 16 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,188 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Hypotension by Assiut University that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06727201Phase 3Assiut UniversityRole of Ondansetron in Spinal Anaesthesia Induced Hypotension | 2026-12-01 |
| NCT06753409Assiut UniversityProcessed Electroencephalography-guided General Anesthesia and Outcomes in Major Abdominal Surgery | 2026-12-01 |
| NCT07869693Assiut UniversityPre-induction Norepinephrine in Septic Patients Undergoing Surgery | 2027-10-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Hypotension by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study was to compare between crystalloid versus crystalloid and colloid combination preloads for prevention of hypotension following intrathecal anaesthesia in patients undergoing elective Caesarean section.
To examine weather baseline perfusion index could predict the incidence of intrathecal-induced hypotension during Caesarean section.
Intrathecal anesthesia is the most commonly used technique for elective Caesarean section all over the world.
One of the most common complications of this technique is hypotension. It's incidence is more than 80% without any prophylactic measures, this hypotension has adverse effects on both mother ( causing nausea and vomiting ) and foetus ( causing acidosis and neurological defects ).
This complication can be managed by several ways like fluid therapy, usage of vasopressors or combination between both of them.
Among the type of fluids ( crystalloid or colloid ) it's still not known which one of them is better. Crystalloid has a short intravascular half-life because of its rapid distribution into the interstitial space. On the other hand colloid remains longer within the intravascular space.
Change in baseline peripheral vascular tone due to pregnancy may affect the degree of such hypotension. The perfusion index ( PI ) derived from a pulse oximeter has been used for assessing peripheral perfusion dynamics due to changes in peripheral vascular tone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will receive 1 L of Ringer's solution as a preload
Drug: Ringer
This group will receive 500 ml of 6% hydroxyethyl starch ( Voluven ) and 500 ml Ringer's solution as a preload
Drug: Ringer · Drug: Voluven
1L of Ringer's solution as a preload in one group.
Also known as: Crystalloid
500 ml of voluven will be given in combination with 500 ml Ringer's solution as a preload in the other group.
Also known as: Hydroxyethyl starch 6%
Incidence of hypotension
Decrease in systolic blood pressure more than 20% of base line
Time frame: 1 hour
Perfusion index
Derived from pulse oximeter
Time frame: 1 hour
Heart rate
Time frame: 1 hour
Urine output
Time frame: 1 hour
No study locations are listed for this record.
Start is estimated for Mar 2018; primary completion for Mar 2019, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HES 130-0.4